E
Valneva SE VALN
$6.63 -$0.16-2.36% NASDAQ
Recommendation
Prev Close
$6.79
Volume
11,485
Avg Vol (90D)
74,615
Market Cap
$576.53M
Dividend & Yield
--
52-Week Range
$3.62 - $9.50
P/E (TTM)
692.86
EPS (TTM)
$0.0098
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/21/2025 - Globe Newswire
Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ Among U.S. Travelers
4/18/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/17/2025 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/17/2025 - Globe Newswire
Valneva (NASDAQ:VALN) Receives "Buy" Rating from HC Wainwright
4/17/2025 - MarketBeat
Valneva SE (VALN, $6.57) entered Downtrend as Momentum indicator drops below 0 level on Apr 16, 2025
4/17/2025 - Tickeron - Stocks
Valneva SE (VALN, $6.57) price exceeded its 50-day Moving Average on April 16, 2025
4/17/2025 - Tickeron - Stocks
Valneva (NASDAQ:VALN) Trading 11.1% Higher - Here's Why
4/16/2025 - MarketBeat
Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ
4/16/2025 - Globe Newswire
Valneva SE: Initiating Hold Rating Based On Potentially Limited Upside
4/16/2025 - SeekingAlpha
Valneva SE (VALN, $7.05) entered Uptrend as Momentum indicator ascends above 0 level on Apr 14, 2025
4/15/2025 - Tickeron - Stocks
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/14/2025 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/14/2025 - PR Newswire
Valneva's Chikungunya Vaccine Gains First Approval in Brazil
4/14/2025 - TipRanks Financial Blog
Valneva Receives First Marketing Authorization for IXCHIQ in a Chikungunya Endemic Country
4/14/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/12/2025 - Globe Newswire
Valneva (NASDAQ:VALN) Sees Strong Trading Volume - Here's What Happened
4/11/2025 - MarketBeat
HC Wainwright Reaffirms "Buy" Rating for Valneva (NASDAQ:VALN)
4/11/2025 - MarketBeat
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
4/10/2025 - Zacks Investment Research
Valneva (NASDAQ:VALN) Trading Up 6.2% - Here's Why
4/10/2025 - MarketBeat
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
4/9/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/8/2025 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/8/2025 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/7/2025 - GuruFocus
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
4/7/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
--
Net Income (TTM)
--
Balance Sheet
Total Assets (Q)
$517.69M
Total Debt (Q)
$223.95M
Total Liabilities (Q)
$330.03M
Book Value Per Share (Q)
$1.16
Cash Flow
Cash from Operations (TTM)
--
Cash from Investing (TTM)
--
Cash from Financing (TTM)
--
Net Change in Cash (TTM)
--
Filings
Filing Date
Monday, March 24, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
1.05
7-Day Total Return
-2.07%
30-Day Total Return
-6.22%
60-Day Total Return
39.87%
90-Day Total Return
60.14%
Year to Date Total Return
40.47%
1-Year Total Return
-18.45%
2-Year Total Return
-41.33%
3-Year Total Return
-80.96%
5-Year Total Return
--
52-week Low
Dec 17, 2024 - $3.62
52-week High
Jun 03, 2024 - $9.50
Valuation
Market Cap
$576.53M - Small Cap
Enterprise Value
$631.11M
Price/Sales (TTM)
8.71
Price/Book (Q)
5.88
Dividends and Shares
Shares Outstanding
170.49M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
valneva.com
Phone Number
33 2 28 07 37 10
Address
6 rue Alain Bombard
Saint-Herblain, 44800
Country
France
Year Founded
1998
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell... more
NASDAQ 04/21/2025 3:59PM Eastern Quotes delayed